var data={"title":"Metronidazole and nystatin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metronidazole and nystatin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/209186?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metronidazole-and-nystatin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metronidazole and nystatin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530152\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flagystatin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530154\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Vaginal;</li>\n      <li>\n        Antiprotozoal, Nitroimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530192\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vaginal infection, mixed:</b> Females: Intravaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal tablet (ovule): Insert 1 tablet daily at bedtime for 10 consecutive days. May repeat for an additional 10 days if cure is not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal cream: Insert 1 applicatorful daily at bedtime for 10 consecutive days. May repeat for an additional 10 days if cure is not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Applicator should not be used after the seventh month of pregnancy. If <i>T. vaginalis</i> is not completely eliminated, oral (systemic) metronidazole should be administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530193\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28842958\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28842959\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, a reduced dose is recommended with severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076311\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, vaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flagystatin: Metronidazole 500 mg and nystatin 100,000 units per applicatorful (55 g) [packaged with  applicator]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, vaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flagystatin Ovule: Metronidazole 500 mg and nystatin 100,000 units (10s) [packaged with applicator]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234082\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28842960\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intravaginal: For vaginal use only. Use only the applicator provided with the product for administration. If using the tablet (ovule), pull applicator plunger back about one inch and insert a tablet into the cup at the end of the hollow tube. Administer one applicatorful (cream) or one applicator with tablet intravaginally. Applicator may be inserted in any comfortable position. Hold the applicator by the barrel, insert gently into the vagina as far as possible without causing discomfort. Press the plunger after it is in proper position in the vagina; withdraw the applicator. Wash applicator in warm water after use. Patients should not use intravaginal products (eg, tampons, douches) for the duration of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530155\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vaginal infection, mixed:</b> Treatment of mixed vaginal infection due to <i>Trichomonas vaginalis</i> and <i>Candida albicans</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530163\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Bitter taste, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, skin rash (located around the knee), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Coated tongue, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal discomfort (granular sensation), vulvovaginal burning</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (including ankles, wrists), joint swelling (including ankles, wrists)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530159\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to metronidazole, nystatin, imidazoles, or any component of the formulation. Combined treatment with oral metronidazole should be avoided in active neurological disorders or in patients with a history of blood dyscrasia, hypothyroidism, or hypoadrenalism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Also refer to Metronidazole (Systemic) monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530160\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic: Metronidazole is possibly carcinogenic based on animal data.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Central or peripheral neuropathy may occur with metronidazole treatment. Monitor and consider discontinuation of therapy if ataxia or other CNS signs/symptoms occur; use with caution in patients with CNS disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Persistent abnormalities have not occurred in clinical trials; monitor total and differential leukocyte counts before and after treatment particularly if a second course of metronidazole is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Systemic absorption of metronidazole from vaginal administration may occur. Adverse effects normally associated with systemic administration of metronidazole may occur following the vaginal administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urine discoloration: Patients should be informed that urine may become darker in color.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cockayne syndrome: Use with caution in patients with Cockayne syndrome; systemic use of metronidazole in this population has been associated with severe hepatotoxicity/acute hepatic failure, sometimes fatal, occurring rapidly after treatment initiation. Discontinue use in patients reporting signs or symptoms of hepatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment due to potential accumulation; dosage adjustment is recommended in these patients. Use caution in patients with hepatic encephalopathy and in patients with a history of livery injury associated with metronidazole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexual partners: Sexual partners should receive concurrent treatment (oral metronidazole) when there is evidence of trichomonal infestation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaginal products: May limit the effectiveness of diaphragms and condoms; concurrent use with treatment is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol consumption: Disulfiram-like reactions to ethanol have been reported with systemic metronidazole and may occur with topical metronidazole; consider avoidance of alcoholic beverages during therapy with topical products and for at least 1 day after.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: May not be effective in bacterial vaginal infections and should not be prescribed unless there is direct evidence of trichomonal infestation or candidiasis. Candidiasis confirmation should be followed up with identification of promoting factors so they can be offset or eliminated. It is recommended that treatment of <i>Candida</i> involve all associated sites concurrently (intestinal, vaginal, or other infections).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fungal replication: Use of soaps with an acid pH, vaginal injections, and tampons may promote fungal replication and should be avoided during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299706\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530185\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10210&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.  Management: Warn patients and monitor for signs and symptoms of a disulfiram-like reaction if patients consume alcohol while using topical metronidazole. Some manufacturers of vaginal metronidazole products list alcohol use within 24 to 72 hours as a contraindication<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased.  Management: Warn patients and monitor for the development of serious CNS toxicity if topical metronidazole is used in a patient taking disulfiram. Some manufacturers of vaginal metronidazole products list disulfiram use within 2 weeks as a contraindication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Lopinavir. Specifically, the use of topical metronidazole with lopinavir/ritonavir solution (which contains 42% alcohol) may result in a disulfiram-like reaction. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progesterone: Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Tipranavir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530156\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Metronidazole crosses the placenta; information for nystatin is not available although systemic absorption is unlikely. The manufacturer does not recommend use of metronidazole during the first trimester of pregnancy or use of this combination product with the applicator after the seventh month of pregnancy. This combination product may decrease the effectiveness of condoms or diaphragms; other forms of contraception should be used during therapy. Also refer to individual agents. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233710\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Metronidazole is present in breast milk; information for nystatin is not available although systemic absorption is unlikely. The manufacturer of this combination product recommends that use in breastfeeding women be avoided. Also refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13270998\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869468\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bio-Vagin (BR);</li>\n      <li>Colpatrin (BR);</li>\n      <li>Etron nistatina (EC);</li>\n      <li>Farm-X Duo (AR);</li>\n      <li>Fladystin (ID);</li>\n      <li>Flagyl Comp (FI);</li>\n      <li>Flagyl Nistatina (BR, CO);</li>\n      <li>Flagystatin (AR, ID, PH, PY, SG, UY);</li>\n      <li>Flagystatin V (MX);</li>\n      <li>Flagystatine (PE);</li>\n      <li>Linfol (AR);</li>\n      <li>Metanis (AR);</li>\n      <li>Metrocaps N (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Metrozin Nistatina (CO);</li>\n      <li>Neo Gynoxa (ID);</li>\n      <li>Nistatina Metronidazol L.C.H. (CL);</li>\n      <li>Nystazole (QA);</li>\n      <li>Provagin (ID);</li>\n      <li>Tratomax (AR);</li>\n      <li>Vagistin (ID);</li>\n      <li>Vanestrin (MX);</li>\n      <li>Vaxigel (PE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Flagystatin (metronidazole and nystatin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc.; February 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10210 Version 73.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2530152\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2530154\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2530192\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2530193\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28842958\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28842959\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076311\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234082\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28842960\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2530155\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2530163\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2530159\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2530160\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299706\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2530185\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2530156\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11233710\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2530189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13270998\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869468\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10210|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metronidazole-and-nystatin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Metronidazole and nystatin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}